NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Bionano Genomics, Inc. (BNGO) Stock Analysis

Bionano Genomics, Inc. (BNGO) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

BNGO

$1.20

−$0.04 (−3.23%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BNGO with… →

BNGO Key Statistics

As of Sep 4, 2026
Trading
Open
$1.25
Previous Close
$1.24
Day's Range
1.20–1.25
52-Week Range
1.00–5.50
Volume
176.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.65
Valuation
Market Cap
$14.13M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.94
Financials (FY)
Revenue (FY)
$28.51M−7.37%
Net Income (FY)
−$26.40M
Profit marginThe share of revenue left as profit after all costs and taxes.
−106.58%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.78M
1-Year Return
−67.03%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
137.22K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BNGO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.57%
2025−91.21%
2024−84.66%
2023−87.05%
2022−51.17%
2021−2.92%
2020+148.39%
2019−76.34%
2018 (partial year)−14.80%

As of September 4, 2026.

BNGO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$28.51M−$26.40M−92.6%
2024$30.78M−$112.02M−364.0%
2023$36.12M−$232.49M−643.7%
2022$27.80M−$132.60M−476.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$28.51M$13.19M−$33.34M−$26.40M−92.6%
2024$30.78M$380.00K−$76.28M−$112.02M−364.0%
2023$36.12M$9.57M−$137.22M−$232.49M−643.7%
2022$27.80M$5.95M−$131.70M−$132.60M−476.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BNGO Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricBNGOMedical Instruments & Supplies medianvs median
P/S ratio0.473.170.1x the median
Profit margin−106.58%0.85%107.4 pts below

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Bionano Genomics, Inc. (BNGO) carries a market capitalisation of $14.13M. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. The company reports 95 employees.

BNGO last closed at $1.20 on September 4, 2026. That is −$0.04 (−3.23%) against the previous close. Over the past 52 weeks the price has ranged from $1.00 to $5.50. The latest close sits 20% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $28.51M. That is −7.37% against the prior fiscal year, when revenue was $30.78M. The same year closed with a net loss of $26.40M. Profit margin runs at −106.59%. That is 107.4 percentage points below the Medical Instruments & Supplies median of 0.85%. Trailing earnings per share are −2.94.

Across the 4 fiscal years on file, revenue moves from $27.80M in 2022 to $28.51M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 0.47 times revenue. On price-to-sales that is 0.1 times the Medical Instruments & Supplies median of 3.17. 55 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.65. Daily returns over the trailing 8 years annualize to a volatility of 188.35%. Over the trailing twelve months the price has returned −67.03%. Across 5 years the annualized return works out at −79.74%.

Growth & Income

The record shows no dividend for BNGO.

2026 is still running; the price is −21.57% year to date. The strongest complete calendar year on file is 2020 at +148.39%; the weakest is 2025 at −91.21%. Of the 7 complete calendar years on file, 1 finished higher.

Peer Comparison

Bionano Genomics, Inc. (BNGO) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Bionano Genomics, Inc. BNGO $14.13M —
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Bionano Genomics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Bionano Genomics, Inc.

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Visit website →